Diagnosis and Management of Choledocholithiasis – Evidence‑Based Guideline

1. Clinical Presentation and Initial Assessment

• Jaundice accompanying right‑upper‑quadrant pain and bile‑duct dilatation in patients with known gallstones signals significant obstruction and warrants urgent evaluation 1.
• The classic cholangitis triad (fever, jaundice, right‑upper‑quadrant pain) defines a high‑risk presentation that requires immediate therapeutic intervention 1.
• Physical inspection of the skin for jaundice is useful when bilirubin is markedly elevated 1.
• Laboratory results (bilirubin, liver enzymes, white‑cell count) are employed for risk stratification rather than as definitive diagnostic tools 1.

2. Imaging Strategy

2.1 Gold‑Standard Modalities

Both MRCP and EUS provide comparable diagnostic performance; no clear superiority is demonstrated when the same patients undergo both tests* 1.

2.2 Choosing Between MRCP and EUS

• MRCP is recommended as the first‑line investigation because it is widely available, non‑invasive, visualises intra‑hepatic ducts, is cost‑effective, suitable for altered gastrointestinal anatomy, and allows image archiving 1.
• EUS is preferred when MRCP is contraindicated or suboptimal, such as in the presence of metallic clips, cardiac pacemakers, mechanical heart valves, severe claustrophobia, morbid obesity, or when expert endoscopists are available 1.

2.3 Role of Ancillary Imaging

• A positive finding of common bile‑duct (CBD) stones on transabdominal ultrasound categorises the patient as high‑risk and should prompt definitive therapy 1.
• CT scanning is useful for detecting malignant biliary obstruction but has limited sensitivity for small CBD stones or stones with density similar to bile 1.
• Endoscopic Retrograde Cholangiopancreatography (ERCP) is primarily therapeutic; its major complication rate ranges from 5 % to 10 % 1, 2.

3. Risk Stratification and Management Pathway

3.1 High‑Risk Patients (Proceed Directly to ERCP)

• CBD stone identified on any imaging modality.
• Clinical cholangitis (fever + jaundice + RUQ pain).
• Combination of pain, duct dilatation, and jaundice in a patient with a history of gallstones.

3.2 Intermediate‑Risk Patients (Require Confirmatory MRCP or EUS)

• Dilated CBD with normal liver‑function tests.
• Abnormal liver‑function tests with a normal‑calibre biliary tree.

3.3 Low‑Risk Patients (Consider Alternative Diagnoses)

• Normal ultrasound and normal laboratory values.

4. Safety Considerations and Clinical Pitfalls

• Ultrasound alone is insufficient for diagnosing choledocholithiasis because it frequently misses stones that MRCP/EUS detect 1.
• Do not perform ERCP in intermediate‑risk patients without prior confirmatory imaging, given the 5‑10 % major complication rate 1.
• Even asymptomatic CBD stones should be treated, as they carry a substantial risk of cholangitis, pancreatitis, and secondary biliary cirrhosis 2.
• Elderly patients undergoing endoscopic sphincterotomy experience up to a 19 % major‑complication rate and a 7.9 % mortality rate 2.

Choledocholithiasis: Pathophysiology, Epidemiology, and Management Guidelines

Pathophysiology

• Migration of gallstones from the gallbladder into the common bile duct (CBD) creates mechanical obstruction that can precipitate life‑threatening complications such as cholangitis, acute pancreatitis, and secondary biliary cirrhosis. 3
• Obstruction leads to biliary stasis and elevated ductal pressure, fostering bacterial overgrowth within the biliary tree. 3
• When bacteria ascend from the duodenum into the obstructed duct, secondary inflammation and infection (cholangitis) develop. 3
• Stones impacted at the ampulla of Vater may block the pancreatic duct, triggering acute pancreatitis. 3
• Prolonged CBD obstruction can cause progressive hepatic injury and, if untreated, evolve into secondary biliary cirrhosis. 3
• Stone size ranges from microscopic sludge to >15 mm; larger stones are more likely to cause complete obstruction and severe clinical sequelae. 3

Epidemiology & At‑Risk Populations

• In the United States, roughly 10–15 % of adults have gallstones, and about 10 % of those individuals develop stones within the CBD. 3, 4
• Among patients already diagnosed with gallbladder stones, approximately 10 % will progress to CBD stones. 3
• Elderly patients experience markedly higher complication rates after intervention, with up to 19 % major complications and a 7.9 % mortality rate. 3

Clinical Management

• Even when asymptomatic, choledocholithiasis warrants definitive intervention because of the substantial risk of obstructive jaundice, cholangitis, acute pancreatitis, and secondary biliary cirrhosis. 3
• Biliary decompression is indicated in nearly all cases; however, initial medical stabilization to address hemodynamic instability and infection should precede definitive therapeutic procedures. 3